Innovent Biologics

Activities: Research & Development Pharmaceutical

Trending Articles

  1. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Indian government bans three medicines owing to health risks Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
  4. Dickson achieves ISO 14001 certification ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
  5. The key role of IVDs in healthcare: challenges to commercialisation and access In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Ingredients

Therapeutic: mazdutide for obesity

Obesity is associated with a wide variety of other conditions and there has been significant interest in the use of diabetic treatments, such as those targeting the glucagon-like peptide-1 (GLP-1) receptor, to assist with weight loss
Research & Development

Innovent Biologics and Synaffix expand ADC collaboration

New deal builds on encouraging preliminary clinical data from the Phase I study of the first antibody-drug conjugate (ADC) developed under the agreement signed in June 2021
Ingredients

Therapeutic: anticancer agent olverembatinib

Gastrointestinal stromal tumours (GISTs) develop in the mesenchymal tissues within the GI tract
Ingredients

Therapeutic: orismilast for psoriasis

Psoriasis, the chronic inflammatory skin disease, remains short of treatment options
Manufacturing

Innovent licenses ProBioGen’s GlymaxX technology

Under this license agreement, Innovent receives non-exclusive rights to use the afucosylation technology GlymaxX for multiple candidates in its pipeline
Finance

Lilly and Innovent to bring oncology therapies to patients in China and around the world

Alliance marks one of the largest biotech drug development collaborations in China
Research & Development

Adimab forms therapeutic discovery partnership with Innovent Biologics

Also receives milestone payments from existing collaborators including Eli Lilly and Kyowa Hakko Kirin
Subscribe now